Shelton Capital Management Cytokinetics Inc Transaction History
Shelton Capital Management
- $3.85 Billion
- Q3 2024
A detailed history of Shelton Capital Management transactions in Cytokinetics Inc stock. As of the latest transaction made, Shelton Capital Management holds 3,995 shares of CYTK stock, worth $202,546. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,995
Previous 3,995
-0.0%
Holding current value
$202,546
Previous $216,000
2.78%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding CYTK
# of Institutions
410Shares Held
125MCall Options Held
4.6MPut Options Held
2.43M-
Black Rock Inc. New York, NY14.7MShares$744 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$596 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.69MShares$491 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.77MShares$394 Million0.07% of portfolio
-
State Street Corp Boston, MA6.46MShares$327 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.77B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...